Influence of CYP2C19 Genotype on the Pharmacokinetics (PK) of Voriconazole

Inclusion criteria

• Healthy male subjects aged 20 - 50 years.
• A body mass index (BMI) in the range 17-28 kg/m2.
• Sufficient ability to understand the nature of the study and any hazards of participating in it. Provide written informed consent after being fully. informed about the study procedures.

Exclusion criteria

• Presence or history of severe adverse reaction to any drug or a history of severe allergic disease.
• Clinically relevant abnormal medical history that could interfere with the objectives of the study.
• Presence or history of eye disease or eye field defect.
• A subject with history of gastrointestinal disease or surgery (except simple appendectomy or repair of hernia), which can influence the absorption of the study drug.
• A subject whose liver function test (AST, ALT, GGT, ALP, LDH) result is over 1.25 times of upper limit of normal range.
• A subject whose SBP is over 140 mmHg or below 90 mmHg and DBP is over 100 mmHg or below 50 mmHg.
• Presence or history of drug abuse.
• Participation in other clinical trial within 2 months.
• Use of a prescription medicine, herbal medicine within 2 weeks or over-the-counter medication within 1 week before first dose.
• Blood donation during 2 months or apheresis during 1 month before the study.
• Presence or history of alcohol abuse.
• Smoking of more than 10 cigarettes/day.
• Use of grapefruit juice, xanthine containing beverage, alcohol or smoking during restriction period.
• Subject judged not eligible for study participation by investigator.